112 related articles for article (PubMed ID: 2452923)
1. Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations.
Colatsky TJ; Bird LB; Knowles JA
J Cardiovasc Pharmacol; 1988 Mar; 11(3):308-16. PubMed ID: 2452923
[TBL] [Abstract][Full Text] [Related]
2. Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes.
Frame LH; Sheldon JH
J Am Coll Cardiol; 1988 Sep; 12(3):746-52. PubMed ID: 3403835
[TBL] [Abstract][Full Text] [Related]
3. Clinical electrophysiological effects of intravenous recainam: an antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias.
Feld GK; Luceri RM; Greenspon AJ; Singh BN; Horowitz LN; Capuzzi DM; Frame VB; Myerburg RJ
Pacing Clin Electrophysiol; 1991 Jul; 14(7):1129-37. PubMed ID: 1715550
[TBL] [Abstract][Full Text] [Related]
4. Cellular electrophysiology of the new antiarrhythmic agent recainam (Wy-42,362) in canine cardiac Purkinje fibers.
Colatsky TJ; Bird LB; Jurkiewicz NK; Wendt RL
J Cardiovasc Pharmacol; 1987 Apr; 9(4):435-44. PubMed ID: 2438506
[TBL] [Abstract][Full Text] [Related]
5. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Cheng JW; Charland SL; Goldfarb S; Spinler SA
Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
[TBL] [Abstract][Full Text] [Related]
6. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction.
Feld GK; Venkatesh N; Singh BN
J Cardiovasc Pharmacol; 1988 May; 11(5):573-80. PubMed ID: 2455844
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.
Anderson JL; Reddy CP; Myerburg RJ; Waxman HL; de Vane PJ
Am J Cardiol; 1993 Mar; 71(8):686-94. PubMed ID: 8447266
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic effects of a new antiarrhythmic agent, recainam, on isolated canine and rabbit myocardial fibers.
Takikawa R; Kamiya K; Kato R; Singh BN
J Am Coll Cardiol; 1988 Apr; 11(4):875-81. PubMed ID: 3351157
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia.
Tai YT; Campbell RW; McComb JM
J Cardiovasc Pharmacol; 1991 Feb; 17(2):310-5. PubMed ID: 1709237
[TBL] [Abstract][Full Text] [Related]
10. Canine electrophysiology of encainide, a new antiarrhythmic drug.
Sami M; Mason JW; Oh G; Harrison DC
Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic, hemodynamic and cardiac electrophysiological evaluation of N-(2,6-dimethylphenyl)-N'-[3-(1-methylethylamino)propyl]urea (Wy-42,362).
Bergey JL; Sulkowski T; Much DR; Wendt RL
Arzneimittelforschung; 1983; 33(9):1258-68. PubMed ID: 6685506
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
[TBL] [Abstract][Full Text] [Related]
13. Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug.
Scatina JA; Kimmel HB; Weinstein V; Troy SM; Sisenwine SF; Cayen MN
Biopharm Drug Dispos; 1990 Jul; 11(5):445-61. PubMed ID: 2207297
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
Troy SM; Cevallos WH; Conrad KA; Chiang ST; Latts JR
J Clin Pharmacol; 1991 May; 31(5):433-9. PubMed ID: 2050828
[TBL] [Abstract][Full Text] [Related]
15. The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients.
Hampton EM; Anastasiou-Nana MI; Nanas JN; Nappi JM; Capuzzi DM; Anderson JL
J Clin Pharmacol; 1987 Dec; 27(12):951-6. PubMed ID: 3437067
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed-chest dog: comparative study with lidocaine.
Karagueuzian HS; Katoh T; McCullen A; Mandel WJ; Peter T
Am Heart J; 1984 Mar; 107(3):418-24. PubMed ID: 6695682
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction.
Lynch JJ; Heaney LA; Wallace AA; Gehret JR; Selnick HG; Stein RB
J Cardiovasc Pharmacol; 1990 May; 15(5):764-75. PubMed ID: 1692937
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart.
Guehler J; Gornick CC; Tobler HG; Almquist A; Schmid JR; Benson DW; Benditt DG
Am J Cardiol; 1985 Mar; 55(6):807-12. PubMed ID: 3919554
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiological effects of Org 7797 in the closed-chest anaesthetized dog.
Leboeuf J; Basiez M; Massingham R
Br J Pharmacol; 1993 Sep; 110(1):23-8. PubMed ID: 8220882
[TBL] [Abstract][Full Text] [Related]
20. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig.
Wiesfeld AC; De Langen CD; Crijns HJ; Bel KJ; Hillege HL; Wesseling H; Lie KI
J Cardiovasc Pharmacol; 1996 Apr; 27(4):594-600. PubMed ID: 8847879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
